Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Saved in:
| Title: | Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials. |
|---|---|
| Authors: | Cohen JA; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA., Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada., DeLuca J; Kessler Foundation, West Orange, NJ, USA.; Department of Physical Medicine & Rehabilitation and Department of Neurology & Neurosciences, Rutgers-New Jersey Medical School, Newark, NJ, USA., Hartung HP; Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.; Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.; Department of Neurology, Medical University of Vienna, Vienna, Austria.; Department of Neurology, Palacký University Olomouc, Olomouc, Czech Republic., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head Organs, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland., Comi G; Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy., Selmaj K; Center for Neurology, Łódź, Poland.; Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland., Steinman L; Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA., Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Montalban X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Havrdová EK; Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty and General University Hospital, Charles University, Prague, Czech Republic., Sheffield JK; Bristol Myers Squibb, Princeton, NJ, USA., Pachai C; Bristol Myers Squibb, Princeton, NJ, USA., Cheng CY; Bristol Myers Squibb, Princeton, NJ, USA., Riolo JV; Bristol Myers Squibb, Princeton, NJ, USA., Cree BA; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Sep; Vol. 31 (10), pp. 1218-1230. Date of Electronic Publication: 2025 Jul 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585251355842 |
